Metformin methods and formulations for treating chronic constipation
AssigneeAGI Therapeutics Research Ltd.
InventorJohn Devane
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods and formulations for treating chronic constipation. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of metformin for treating chronic constipation and further comprise at least one pharmaceutically acceptable ingredient to control the release of the metformin, wherein following administration, the release of metformin is distal to the gastrointestinal sites to achieve systemic absorption of metformin. The invention is also directed to treating constipation as a symptom associated with other diseases and conditions such as irritable bowel syndrome.
Claims44
A method for treating chronic constipation in a subject in need of such treatment comprising administering to the subject a dosage formulation comprising a therapeutically effective amount of metformin, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable ingredient to control the release of the metformin, wherein following administration, the dosage formulation releases the metformin distal to the gastrointestinal sites at which metformin is absorbed.
A dosage formulation comprising a therapeutically effective amount of metformin, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable ingredient to control the release of metformin, wherein the dosage formulation releases metformin distal to the gastrointestinal sites at which metformin is absorbed.
A modified-release pharmaceutical tablet comprising a therapeutically effective amount of metformin, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable ingredient to control the release of metformin, wherein the modified release tablet exhibits a dissolution profile wherein after about two hours, less than about 10% of the metformin is released in a medium with a pH less than or equal to about 6.5.
A modified-release pharmaceutical tablet comprising a therapeutically effective amount of metformin, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable ingredient to control the release of metformin, wherein the modified release tablet exhibits a dissolution profile such that after about two hours, less than about 10% of the metformin is released in a medium with a pH less than or equal to about 5.
Dependencies are inferred from the claim text.